50 PRIMECAP Management Lilly(Eli) Trades
PRIMECAP Management's position in Lilly(Eli) is currently worth $9.03B. It makes up 6.57% of their stock portfolio and is their biggest holding. The investor owns 1.30% of the outstanding Lilly(Eli) stock. The first Lilly(Eli) trade was made in Q1 2013. Since then PRIMECAP Management bought shares twelve more times and sold shares on 37 occasions. The stake costed the investor $681M, netting the investor a gain of 1226% so far.
News about Lilly(Eli) & Co and PRIMECAP Management
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook
Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term inve...
Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
No summary available.
Avalo Acquires Anti-IL-1¦Â mAb and Announces Private Placement Financing of up to $185 Million
Avalo acquires Phase 2-ready anti-IL-1¦Â mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis supp...
Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?
Free two-day shipping for Prime members and a direct-to-consumer sales model could accelerate sales of Eli Lilly''s Zepbound.